Literature DB >> 27697806

Drug therapies in type 2 diabetes: an era of personalised medicine.

Tahseen A Chowdhury1, Paul Grant2.   

Abstract

Optimal management of diabetes involves a multidisciplinary approach. Prioritisation of lifestyle change, blood pressure and lipid control, and regular screening for complications are advocated in most international guidelines. Good glucose control, however, remains an important aim of treatment, although it is increasingly recognised that glucose targets should be individualised, with less stringent targets for older patients with significant comorbidities.In recent years, a number of newer therapies for hyperglycaemia have become available. This review aims to discuss currently available options for patients with type 2 diabetes, and also discusses potential new therapies that may be on the horizon in the future. © Royal College of Physicians 2016. All rights reserved.

Entities:  

Keywords:  Diabetes; hyperglycaemia; therapy

Mesh：

Substances：

Year:  2016        PMID： 27697806      PMCID： PMC6297289          DOI： 10.7861/clinmedicine.16-5-441

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  26 in total

Review 1.  Repaglinide: a review of its use in type 2 diabetes mellitus.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2012-01-22       Impact factor: 9.546

Review 2.  Cellular and molecular mechanisms of metformin: an overview.

Authors:  Benoit Viollet; Bruno Guigas; Nieves Sanz Garcia; Jocelyne Leclerc; Marc Foretz; Fabrizio Andreelli
Journal:  Clin Sci (Lond)       Date:  2012-03       Impact factor: 6.124

3.  Combination of insulin and metformin in the treatment of type 2 diabetes.

Authors:  Michiel G Wulffelé; Adriaan Kooy; Philippe Lehert; Daniel Bets; Jeles C Ogterop; Bob Borger van der Burg; Ab J M Donker; Coen D A Stehouwer
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

4.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

Authors:  Renata Belfort; Stephen A Harrison; Kenneth Brown; Celia Darland; Joan Finch; Jean Hardies; Bogdan Balas; Amalia Gastaldelli; Fermin Tio; Joseph Pulcini; Rachele Berria; Jennie Z Ma; Sunil Dwivedi; Russell Havranek; Chris Fincke; Ralph DeFronzo; George A Bannayan; Steven Schenker; Kenneth Cusi
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

5.  Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial.

Authors:  Julio Rosenstock; Daniel L Lorber; Luigi Gnudi; Campbell P Howard; David W Bilheimer; P-C Chang; Richard E Petrucci; Anders H Boss; Peter C Richardson
Journal:  Lancet       Date:  2010-06-26       Impact factor: 79.321

6.  Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.

Authors:  Kim Henriksen; Inger Byrjalsen; Per Qvist; Henning Beck-Nielsen; Gitte Hansen; Bente J Riis; Hans Perrild; Ole Lander Svendsen; Jeppe Gram; Morten A Karsdal; Claus Christiansen
Journal:  Diabetes Metab Res Rev       Date:  2011-05       Impact factor: 4.876

7.  10-year follow-up of intensive glucose control in type 2 diabetes.

Authors:  Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil
Journal:  N Engl J Med       Date:  2008-09-10       Impact factor: 91.245

8.  The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan.

Authors:  Ramazan Sari; Mustafa Kemal Balci; Sadika Halide Akbas; Berkant Avci
Journal:  Endocr Res       Date:  2004-05       Impact factor: 1.720

Review 9.  The physiology of glucagon-like peptide 1.

Authors:  Jens Juul Holst
Journal:  Physiol Rev       Date:  2007-10       Impact factor: 37.312

Review 10.  Oral insulin delivery: how far are we?

Authors:  Pedro Fonte; Francisca Araújo; Salette Reis; Bruno Sarmento
Journal:  J Diabetes Sci Technol       Date:  2013-03-01
View more
  4 in total

1.  Diabetes remission: a realistic goal?

Authors:  Tahseen A Chowdhury
Journal:  Clin Med (Lond)       Date:  2018-03       Impact factor: 2.659

Review 2.  Current perspective on the role of insulin and glucagon in the pathogenesis and treatment of type 2 diabetes mellitus.

Authors:  Ashutosh Ojha; Utkarsh Ojha; Raihan Mohammed; Abhinaya Chandrashekar; Harsh Ojha
Journal:  Clin Pharmacol       Date:  2019-05-09

3.  1,25-dihydroxyvitamin-D3 promotes neutrophil apoptosis in periodontitis with type 2 diabetes mellitus patients via the p38/MAPK pathway.

Authors:  Yaping Tang; Junyu Liu; Yanmei Yan; Hui Fang; Chengwei Guo; Ruidi Xie; Qi Liu
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

Review 4.  Emerging Roles of BRD7 in Pathophysiology.

Authors:  Sang Won Park; Junsik M Lee
Journal:  Int J Mol Sci       Date:  2020-09-27       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.